HDAC inhibitors (HDACi) vorinostat, belinostat, and panobinostat, targeting HDAC class I, II, and IV, and romidepsin, a specific HDAC 1 and 2 inhibitor, are currently approved for hematological malignancies [228,230]. This evidence concerns the gene HDAC9 and hematologic disorder.